A detailed history of J. Goldman & CO LP transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 34,367 shares of ITOS stock, worth $282,840. This represents 0.01% of its overall portfolio holdings.

Number of Shares
34,367
Previous 69,585 50.61%
Holding current value
$282,840
Previous $1.03 Million 66.09%
% of portfolio
0.01%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.09 - $17.97 $355,349 - $632,867
-35,218 Reduced 50.61%
34,367 $350,000
Q2 2024

Aug 14, 2024

SELL
$10.33 - $18.09 $129,827 - $227,355
-12,568 Reduced 15.3%
69,585 $1.03 Million
Q1 2024

May 15, 2024

BUY
$9.89 - $13.64 $812,493 - $1.12 Million
82,153 New
82,153 $1.12 Million
Q2 2021

Aug 16, 2021

SELL
$17.9 - $36.1 $753,768 - $1.52 Million
-42,110 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$30.86 - $44.2 $1.3 Million - $1.86 Million
42,110 New
42,110 $1.44 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $293M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.